The FDA Just Moved to End Compounded GLP-1s. Here’s How to Transition Your Patients.
Reading Time: 10 minutesA physician’s guide to the FDA’s April 30 proposed rule ending the 503B compounded GLP-1 pathway — and how to transition patients safely.
News
Time-sensitive clinical and regulatory news — FDA actions, CMS coverage decisions, new device clearances, drug approvals. Updated 2-3x per week.
FDA Approves Foundayo: A New Oral GLP-1 Weight Loss Drug
Reading Time: 4 minutesObesity medicine just got a major shake-up today with the U.S. Food and Drug Administration’s approval of Foundayo (orforglipron). Eli Lilly developed this drug. And this is a big deal because Foundayo…
Wegovy Subscription Program: Novo Nordisk’s New Approach to Access
Reading Time: 4 minutesNovo Nordisk, the manufacturer of the popular GLP-1 medication Wegovy (semaglutide), has introduced a new multi-month subscription program designed to make this FDA-approved obesity treatment more accessible and affordable for self-pay patients…